Pulmatrix, Inc. PULM

Eos SENOLYTIX, led by Kevin Slawin, will present at the 17th World Congress on Targeting Mitochondria in Berlin and host a panel on mitochondrial science. Lead candidate PTC-2105 (MitoXcel geropeptide) is in IND-enabling preclinical studies for sarcopenia and sarcopenic obesity, with Tufts’ Roger Fielding and Mayo Clinic’s Nathan LeBrasseur as co-Principal Investigators. In preclinical aged-mice work, PTC-2105 reduced fat—visceral and total—while increasing lean mass and improving physical function, with a potential healthspan benefit described as a “lifespan extension dividend.” Eos plans to merge with Pulmatrix, Inc. (PULM); if completed, the combined company would trade under MTXL and pursue pipeline advancement through key milestones. Pulmatrix’s iSPERSE inhaled therapy platform for migraine and respiratory diseases remains its core business. The release includes standard forward-looking statements and regulatory cautions. Merger could substantially alter Pulmatrix’s strategic direction and market trajectory.

Pulmatrix, Inc. (PULM) released second quarter 2026 financial results and reported progress on its merger. Merger progress combined with quarterly results signals major strategic moves that can alter company trajectory.

Pulmatrix announced Q2 2024 financial results, completed transactions with MannKind, and provided updates on clinical assets PUR3100, PUR1800, and PUR1900. Significant impact likely on future and performance due to completed transactions, financial results, and updates on key clinical assets.

Pulmatrix, Inc. (PULM) announced first quarter 2026 financial results. Quarterly financial results directly shape investor sentiment, valuation, and stock trajectory for biotech firms like PULM.

Pulmatrix, Inc. (PULM) reported its financial results for the first quarter of 2025, highlighting a strategic divestment plan aimed at optimizing its asset portfolio. The company aims to streamline operations and focus on core areas that promise growth and innovation. Details of the financial performance indicate a need for restructuring to enhance shareholder value and improve market positioning. The divestment plan and financial results indicate significant strategic shifts that could alter the company's trajectory and investor sentiment.

Pulmatrix announces positive results for orally inhaled DHE for acute migraine in a Phase 1 trial, positioning it for a Phase 2 study. Positive Phase 1 trial results and potential for Phase 2 study could significantly impact Pulmatrix's future and market performance.

Pulmatrix, Inc. (PULM) closed a preferred stock transaction to fund its planned merger. Closing preferred stock financing advances a planned merger, a major strategic move likely to alter company trajectory and investor sentiment.

Pulmatrix, Inc. (PULM) and Eos SENOLYTIX announced a merger agreement to combine resources and advance novel mitochondrial therapies aimed at improving healthspan. Merger with Eos SENOLYTIX provides Pulmatrix access to senolytic technologies, significantly expanding its pipeline and altering its biotech trajectory.

Pulmatrix, Inc. (PULM) terminates its prior planned merger and continues pursuing alternative merger opportunities. Termination of a planned merger while seeking alternatives marks a major strategic shift with significant potential to alter Pulmatrix's trajectory and investor sentiment.

Pulmatrix, Inc. (PULM) announced year-end and fourth quarter 2025 financial results. Year-end financial results reveal operational performance and cash position, moderately influencing investor sentiment and stock trajectory.

Pulmatrix, Inc. and Cullgen are actively pursuing a merger while simultaneously granting each other waivers to explore alternative options. This strategic move indicates both companies are considering various pathways to enhance their business prospects amidst ongoing discussions. The merger discussions and waivers suggest potential shifts in strategic direction that could moderately influence Pulmatrix's market positioning.

Pulmatrix, Inc. (PULM) reported its financial results for the third quarter of 2025, highlighting a strategic divestment plan for its migraine and inhalation assets. The company aims to streamline operations and focus on core areas, which may enhance its financial health and operational efficiency moving forward. The divestment plan represents a significant strategic shift that could alter the company's trajectory and investor sentiment.

Pulmatrix, Inc. (PULM) reported its financial results for the second quarter of 2025, highlighting a strategic divestment plan for its inhalation assets. The company aims to streamline operations and focus on core areas, which may enhance its financial health and operational efficiency moving forward. The divestment plan represents a significant strategic shift that could alter the company's trajectory and investor sentiment.

Pulmatrix, Inc. (PULM) announced its financial results for the year-end and fourth quarter of 2024, highlighting key metrics and performance indicators. The company also revealed a divestment plan aimed at optimizing its asset portfolio, which is expected to streamline operations and focus on core business areas. The divestment plan and financial results indicate significant strategic moves that could alter the company's trajectory and investor sentiment.

Cullgen has initiated Phase 1 dosing of its oral pan-TRK protein degrader, aimed at treating acute and chronic pain. This potential first-in-class treatment is expected to address significant unmet medical needs in pain management. The trial will evaluate the safety, tolerability, and pharmacokinetics of the drug, marking a critical step in Cullgen's development pipeline. The advancement of Cullgen's drug could influence market dynamics and competitive positioning in the pain management sector.

Pulmatrix and Cullgen announce proposed merger. The merger between Pulmatrix and Cullgen is a significant strategic move that could alter Pulmatrix's trajectory and investor sentiment.

Pulmatrix reported a revenue of US$1.55m, with a net loss of US$5.81m in the second quarter of 2024, resulting in a loss of US$1.59 per share. The significant widening of the net loss and per share loss in the second quarter of 2024 is likely to have a major impact on Pulmatrix's future performance and investor sentiment.

Pulmatrix and MannKind enter cross license agreement and transfer of laboratory. MannKind to provide future iSPERSE™ dry powder drug formulation services to Pulmatrix. The agreement involves significant strategic moves and potential for transformative technologies that could alter Pulmatrix's competitive position.

Pulmatrix announces first quarter financial results and provides corporate update, including patient dosing for Phase 2b study of PUR1900 for ABPA and positive topline results for Phase 1 study of PUR3100 for migraine. Significant impact likely on future and performance with advancements in key development programs and extended cash runway.

Pulmatrix reports first quarter 2024 earnings with revenue up 293% and net income of US$825.0k. The financial results show a moderately noticeable influence on Pulmatrix's future performance.

Pulmatrix announces Q1 2024 financial results, ends Phase 2b study for PUR1900, focuses on PUR3100 and PUR1800 development. Significant impact expected due to strategic changes in development programs and financial results.

Pulmatrix announces year-end financial results, ends Phase 2b study for PUR1900, and provides corporate update. Significant impact expected due to financial results, strategic changes, and focus on key development programs.

Pulmatrix stops patient enrollment for PUR1900 Phase 2B study, closes study to focus on strategic alternatives with partner Cipla. The decision to halt the study and focus on strategic alternatives with a partner indicates a significant shift in the company's trajectory and potential future developments.

Pulmatrix announces Q3 2023 financial results and updates on clinical programs for PUR1900, PUR3100, and PUR1800. Significant impact expected on future performance with progress in clinical trials and potential partnerships.

FDA accepts IND application for PUR3100 to treat acute migraine. Acceptance of IND application for Phase 2 study on PUR3100 could significantly impact Pulmatrix's future and market performance.

Pulmatrix announces low likelihood of drug-drug interactions with PUR1900, Phase 2 study ongoing for ABPA and Asthma. Publication of potential drug-drug interaction data and Phase 2 study for ABPA and Asthma could significantly impact Pulmatrix's future drug development and market performance.

Pulmatrix announces Q2 2023 financial results and corporate update, including progress on Phase 2 trials for PUR1900 and IND submission for PUR3100. Significant impact expected on future performance with advancements in clinical trials and potential partnerships.

Pulmatrix submits IND application to FDA for Phase 2 trial of PUR3100 to treat acute migraine. Submission of IND application for Phase 2 trial of new drug has significant impact on Pulmatrix's future and market performance.

Pulmatrix presents Phase 1 data for PUR3100 at American Headache Society meeting. Phase 1 data for PUR3100 shows potential for significant impact on future drug development and market positioning.

Pulmatrix to present at BIO International Convention showcasing positive Phase 1 results for acute migraine treatment. Presentation of positive Phase 1 results and potential partnership opportunities could significantly impact Pulmatrix's future trajectory.